Cellular senescence is a state of stable, terminal cell cycle arrest associated with various
macromolecular changes and a hypersecretory, pro-inflammatory phenotype. Entry of cells …

Cellular senescence, first described in vitro in 1961, has become a focus for biotech
companies that target it to ameliorate a variety of human conditions. Eminently characterized …

Although melanoma is notorious for its high degree of heterogeneity and plasticity,, the
origin and magnitude of cell-state diversity remains poorly understood. Equally, it is unclear …

Glioblastoma (GBM) is an incurable primary malignant brain cancer hallmarked with a
substantial protumorigenic immune component. Knowledge of the GBM immune …

Chronological age represents the single greatest risk factor for human disease. One
plausible explanation for this correlation is that mechanisms that drive ageing might also …

INTRODUCTION Therapies targeted against the tumor microenvironment (TME) represent a
promising approach for treating cancer. This appeal arises in part from the decreased …

Glioblastoma multiforme (GBM) comprises several molecular subtypes, including proneural
GBM. Most therapeutic approaches targeting glioma cells have failed. An alternative strategy …

Obesity has become more prevalent in most developed countries over the past few decades,
and is increasingly recognized as a major risk factor for several common types of cancer. As …

Cellular senescence disables proliferation in damaged cells, and it is relevant for cancer
and aging. Here, we show that senescence occurs during mammalian embryonic …

Promotion of the cell cycle is a major oncogenic mechanism of the oncogene c-MYC (MYC).
MYC promotes the cell cycle by not only activating or inducing cyclins and CDKs but also …